Telegraph

7x24 real-time news feed, auto refreshBeijing Time：

🔄 Auto refresh 🔔 Sound 💬 Notify

All A·Important B·Normal #Virus ✕

[Kenya has a new confirmed case of Ebola] October 19th, Patrick Amos, director of the Health Services Directorate of the Kenyan Ministry of Health, said on the evening of October 18th local time that Kenya tested 38 people for Ebola virus that day, and one of them tested positive. Amos said that the confirmed patient is a 49-year-old male who is not a medical worker and has symptoms such as fever, headache and muscle pain. Currently, the total number of confirmed cases of Ebola in Kenya has risen to eight, including one death.

#Virus10-19 03:51

[Tanzania strengthens entry health screening to prevent the import of Ebola virus] On October 17th, the Ministry of Health of Tanzania issued the latest travel health tips on the 17th local time, announcing the strengthening of border health prevention and control measures, requiring all incoming passengers to fill in a health monitoring declaration form and undergo health screening at airports, land ports and seaports to prevent the introduction of infectious diseases such as Ebola. According to the latest guidelines issued by the Ministry of Health of Tanzania, all incoming passengers must fill out a health monitoring declaration form through the Ministry of Health’s online platform, which can be completed before departure or after arriving in Tanzania. Passengers should fill in the relevant information truthfully and keep the QR code or declaration number generated by the system for verification by the health department upon entry. At the same time, Tanzania will strengthen health checks at all ports of entry, including temperature checks for passengers. For people suspected of being infected with Ebola or other infectious diseases, the health department will conduct further assessments in accordance with relevant national prevention and control procedures and take corresponding measures. For those identified as being at high risk of infection, the health department will implement mandatory health monitoring for 21 days and follow up through daily messages or other communication methods. The health department also requires travelers to pay close attention to their health conditions and promptly report to the nearest medical institution or border health department if they develop symptoms that may be related to Ebola or other infectious diseases. Recently, Tanzania's neighboring country Kenya confirmed three imported cases of Ebola virus, including one death. Tanzania's strengthening of entry health screening this time aims to strengthen disease surveillance and early detection capabilities and reduce the risk of cross-border spread of infectious diseases such as Ebola. (CCTV News)

#Virus #Global market intelligence10-17 23:31

[WHO: Saudi Arabia reports 8 cases of Middle East respiratory syndrome coronavirus] October 17th, the World Health Organization stated on the 16th that between January 1 and October 5, 2026, Saudi Arabia reported 8 laboratory-confirmed cases of Middle East respiratory syndrome coronavirus infection, including 1 death. The WHO stated that 8 cases were distributed in 6 locations, and no epidemiological link was found between all cases. Two cases reported direct contact with camels, while 6 cases reported no known contact history with camels. These cases appear to represent sporadic infections associated with zoonotic spillover rather than a single outbreak cluster. Saudi health authorities have conducted contact tracing of all confirmed cases; so far, no secondary cases have been found.

#Epidemiology #Virus #Futures Market Intelligence #middle east conflict10-17 02:07

[Kenya reports the country’s third Bundibugyo Ebola case] On October 17, Kenya’s Ministry of Health confirmed on the 16th local time that there was a new confirmed case of Ebola in the country. This is the third confirmed case reported in Kenya in this round of the epidemic. It is reported that the newly diagnosed patient is a 65-year-old woman who is closely related to the first and second previously diagnosed patients. The patient has been in isolation since October 6, during which time he was tested and the result showed that he was infected with Bundibugyo Ebola virus. Currently, she has been transferred to a designated treatment center for treatment.

#Virus10-17 00:18

[Russia launches epidemiological investigation into suspected monkeypox epidemic in Moscow State] On October 16th, the Moscow State Branch of the Russian Federal Service for Consumer Rights Protection and Public Welfare Supervision issued a notice on its official website on the 15th that it had launched an epidemiological investigation into the suspected monkeypox epidemic in the state and had taken relevant epidemic prevention measures. The notice stated that after a suspected case of monkeypox appeared in Moscow Oblast, an epidemiological investigation was immediately carried out and comprehensive epidemic prevention measures were taken, including identifying contact groups and implementing disinfection work. Currently, 5 people have been admitted to the hospital for medical observation. The notice stated that the high-tech detection system developed by the Russian Federal Service for Consumer Protection and Public Welfare Supervision can quickly detect the monkeypox virus in a short period of time.

#Epidemiology #medicine #Virus #Global market intelligence10-16 06:40

[Influenza activity has fluctuated recently, and the test positivity rate in southern provinces is at a moderate epidemic level] October 15th, according to the national sentinel surveillance of acute respiratory infectious diseases released by the Chinese Center for Disease Control and Prevention today (15th), from October 5th to October 11th, currently, respiratory infectious diseases are at a low level in most parts of the country, and influenza activity has fluctuated, mainly A (H3N2) subtype and B (Victoria) influenza viruses. In addition, there is a significant difference in influenza activity levels between the northern and southern provinces. The test positivity rate in the southern provinces fluctuates at the medium epidemic level, while the northern provinces are at the low epidemic level. The Chinese Center for Disease Control and Prevention reminds that people with weak immunity, such as pregnant women, young children, the elderly and patients with chronic diseases, should receive relevant vaccines to prevent respiratory infectious diseases according to vaccination guidelines and take personal protection.

#Virus #vaccine #influenza10-15 22:06

[Wantai Bio: Freeze-dried recombinant respiratory syncytial virus vaccine approved for clinical trials] On October 12, Wantai Bio (603392.SH) announced that the company's wholly-owned subsidiary Wantai Canghai received the "Drug Clinical Trial Approval Notice" for the freeze-dried recombinant respiratory syncytial virus vaccine (CHO cells) approved and issued by the State Food and Drug Administration, and agreed to conduct clinical trials to prevent lower respiratory tract diseases caused by RSV infection in people aged 60 and above. The vaccine is an adjuvant-free freeze-dried preparation. Preclinical data shows good safety, but the development and marketing cycle is long and there are uncertainties.

#clinical trial #cell #Virus #vaccine #A-share announcement express10-12 16:01

[The price of self-paid influenza vaccines has generally rebounded, and the price of free vaccines has stabilized at around 9 yuan/tube] On October 11, reporters recently visited community health service centers in Shenzhen, Shanghai, and Nanjing and found that the number of appointments for some outpatient clinics was tight, but the vaccine inventory was relatively sufficient. In terms of price, the selected prices of some trivalent split vaccines in Shanghai range from 86.4 yuan to 96.4 yuan per dose. Self-funded influenza vaccines (non-immunization program) such as Hualan Vaccine, Changchun Biotech, Zhejiang Tianyuan, Fosun Yalifeng, and Beijing Sinovac have seen price increases to varying degrees; while the prices of some government procurement projects for key groups (immunization program vaccines) are still around 9 yuan/tube. An official from a head flu vaccine company told reporters that the company's production this year has increased significantly compared with previous years, and plans to exceed 25 million doses. However, due to the adjustment of virus strains, the batch release progress has been delayed compared with previous years. Xiaocai's note: In February 2026, the World Health Organization announced the recommended components of the northern hemisphere influenza vaccine for 2026-2027, and no longer included B/Yamagata viruses in the recommended formula. The vaccination guide for this epidemic season released by the Chinese Center for Disease Control and Prevention in September showed that the influenza vaccines on the market in China in 2026-2027 only include trivalent inactivated vaccines and trivalent live attenuated vaccines. (Reporters Lu Afeng and Yu Miao)

#Virus #vaccine #Tongcheng10-11 19:22

On October 10, the U.S. Food and Drug Administration (FDA) approved a drug for the treatment of skin lesions caused by the herpes simplex virus.

#Virus #Futures Market Intelligence #biopharmaceutical10-10 00:50

[Jindic: Trivalent influenza vaccine has obtained a drug registration certificate, annual revenue may be less than 100 million yuan and may be subject to delisting risk warning] On October 9th, Jindike (688670.SH) announced that the company recently received the "Drug Registration Certificate" for the influenza virus split vaccine approved by the State Food and Drug Administration. Affected by the WHO's adjustment to the recommended components of influenza vaccines, the company will no longer sell quadrivalent influenza vaccines this influenza season, and will only sell trivalent influenza vaccines. Because the product has just been approved, there are currently no products available for sale, and the time window for large-scale sales has been missed. After preliminary calculations, it is expected that the full-year revenue may be less than 100 million yuan and the company will not be able to turn around losses. If it encounters a financial delisting risk warning situation, the Shanghai Stock Exchange will implement a "delisting risk warning" on the company's stocks.

#Virus #vaccine #A-share announcement express10-09 18:51

[WHO: Congo (DRC) Ebola epidemic spreads to new areas] September 26th, the World Health Organization said on the 25th that the Bundibugyo Ebola virus has spread to more areas in the Congo (DRC). Currently, there are cases in 63 health districts in 7 provinces in the country. According to media reports citing WHO data, as of September 23, Congo (DRC) had reported a total of 7,890 confirmed cases of Ebola and 3,799 deaths.

#Virus09-26 10:57

[Foot-and-mouth disease outbreak in Namibia] On September 24, the Ministry of Agriculture, Fisheries, Water Resources and Land Reform of Namibia announced on the 23rd that an outbreak of foot-and-mouth disease has occurred in the country, and has suspended the movement, import and export of all cloven-hoofed animals and related products in the domestic market. Namibia's Ministry of Agriculture issued a statement on the same day saying that a farm in the country's Karas District tested positive for foot disease. After the relevant departments discovered that 63 cows on the farm showed symptoms of foot and mouth disease on the 22nd, they collected samples from 11 symptomatic cows and sent them for testing. Test results on the 23rd showed that 10 of the samples were positive for foot-and-mouth disease virus. Karas District was previously certified as a "foot-and-mouth disease-free area" by the World Organization for Animal Health. The Ministry of Agriculture of Namibia announced a nationwide suspension of the movement of cloven-hoofed animals and related products, and also suspended the import and export of cloven-hoofed animals and related products. It will immediately strengthen monitoring to find out the full situation of the epidemic. (CCTV News)

#Virus #animal #Global market intelligence09-24 20:45

[Chengda Biotech: Signed Recombinant Tetravalent Enterovirus Vaccine Technology Transfer Contract] On September 24, Chengda Biotech (688739.SH) announced that the company signed a "Recombinant Quadrivalent Enterovirus Vaccine Technology Transfer Contract" with Wiltek, and transferred all rights and interests of the recombinant quadrivalent enterovirus vaccine (Hansenula yeast) project. The technology transfer fee is 46 million yuan (tax included), which will be paid in installments based on milestones; sales commissions and sales milestone rewards will be paid based on the sales of the product after it is launched. The subject product is still in the early stages of research and development, and there are uncertainties in subsequent clinical trials, registration approval and commercialization.

#clinical trial #Virus #vaccine #A-share announcement express09-24 17:20

[The God 23 crew has been on a business trip for nearly 4 months] According to reports on September 21, the God 23 crew has been in orbit for nearly 4 months, and its space science experimental tasks continue to advance. Recently, astronauts have conducted research on the space interaction between viruses and immune metabolism, accumulating key data for long-term on-orbit health protection. At the same time, the three astronauts completed personal noise exposure dose measurements as planned, as well as regular cleaning, inspection and maintenance of the cabin environment. (CCTV Military)

#aerospace #Virus09-21 08:20

[28 "Xinwen Lianbo" important news items for Saturday, September 19th] September 19th, the main contents of today's "Xinwen Lianbo" are: 1. [New ideas lead a new journey] Dahe Runhuaxia; 2. [Continue the spirit of the Long March and forge ahead on the journey of rejuvenation] Hunan: a red hot land heading towards the new; 3. The high-end transformation of China’s manufacturing industry is accelerating; 4. In the first eight months, the national general public budget revenue increased by 5.7% year-on-year; 5. In the first eight months, nearly 700 billion yuan was invested in water conservancy construction nationwide; 6. Carry out various forms of mass national defense education activities in various places; 7. China’s aerospace health security system has reached the internationally advanced level; 8. [Cultural China Tour] Zhu Xiyuan: The living water of cultural context flows today; 9. The 20th Asian Games opens today; 10. The “15th Five-Year Plan” for Cultural Industry Development was released; 11. From January to August, national railways carried 3.32 billion passengers; 12. China has launched new measures to accelerate the cultivation of comprehensive talents in the digital economy; 13. Publicly solicit opinions on regulations to protect the health and safety of minors using the Internet; 14. Russia requires Japan to withdraw the "Typhon" missile system deployed in Japan; 15. The Houthi armed forces in Yemen said they were under intensive air strikes by Saudi Arabia. The Saudi capital issued the first air defense warning in this round of conflict; 16. China emphasizes that United Nations peacekeeping operations should serve the political process; 17. Denmark and its autonomous territory Greenland reached an agreement with the United States; 18. Russia claims that the "trinity" nuclear force is still the guarantee of Russia's sovereignty; 19. The spread of West Nile virus in Italy has intensified.

#aerospace #Virus #news broadcast09-19 20:11

[Italy has reported more than 650 cases of West Nile virus infection this year] September 19th, according to data released by the Italian health department on the 18th, Italy has reported more than 650 cases of West Nile virus infection since the beginning of this year, accounting for about half of the total cases in Europe. Local researchers said that high temperatures caused by climate warming are conducive to mosquito breeding, causing West Nile virus to spread more widely and extend the transmission season. West Nile virus is typically transmitted to humans or other mammals through mosquito bites. Infected people will experience symptoms such as fever and body aches. Elderly people and patients with chronic diseases may develop neurological diseases such as encephalitis or even die after infection. There are currently no approved vaccines or specific drugs against this virus. (CCTV News)

#mammal #Virus #animal #vaccine #Global market intelligence09-19 14:34

[Merck’s new formulation of Premin® Letermovir Tablets (II) is launched in China] On September 16, Merck announced that its new non-nucleoside cytomegalovirus (CMV) inhibitor Premin®’s new dosage form Letermovir Tablets (II) has been officially launched in China It is marketed in China for the prevention of cytomegalovirus infection and cytomegalovirus disease in adults and pediatric recipients 6 months and older and weighing ≥6kg who are seropositive for cytomegalovirus (CMV) who have received allogeneic hematopoietic stem cell transplantation (HSCT) [R+].

#stem cells #Gene #cell #Virus #medicine09-16 17:06

[Chile becomes the first country in South America to eliminate dog-to-human rabies] September 15th, the World Health Organization said on the 14th that thanks to Chile’s continuous prevention and surveillance work in the field of public health for more than 50 years, the country has become the first country in South America to eliminate dog-to-human rabies. According to reports, the WHO said that the last case of dog-to-human rabies in Chile was in 1972. In the following decades, Chile eliminated dog-to-human rabies through mass vaccination of pets, vaccination of people who may have been exposed to related viruses, strengthening dog management, and community education.

#public health #Virus #vaccine09-15 12:39

[Three people have died due to West Nile virus infection in the Netherlands] September 10th, according to a report from the Dutch National Institute of Public Health and the Environment on September 10, local time, there were 9 new cases of West Nile virus infection in the Netherlands last week. Since the beginning of this year, a total of 18 cases of West Nile virus infection have been reported in the Netherlands, including 3 deaths.

#public health #Virus #Global market intelligence09-10 21:00

[Watson Bio: Subsidiary's new coronavirus mRNA vaccine approved for marketing] On September 10th, Watson Bio (300142.SZ) announced that the company's wholly-owned subsidiary Yuxi Watson received the "Drug Registration Certificate" for the "new coronavirus mRNA vaccine" approved and issued by the State Food and Drug Administration. This vaccine is a third-generation COVID-19 vaccine iteratively developed based on mRNA platform technology. The antigen sequence is designed based on the S protein of the OmicronJN.1 strain. It is used to prevent diseases caused by COVID-19 infection in people aged 18 years and above. The company does not expect the approval of the vaccine to have a significant impact on its 2026 results.

#RNA #Virus #vaccine #A-share announcement express09-10 19:50

[Shi4 Pharmaceutical Group: Letermovir Injection received drug production registration approval] On September 10th, Shi4 Pharmaceutical Group issued a voluntary announcement that the company has obtained the drug production registration approval document from the China National Medical Products Administration for Letermovir Injection (12ml:240mg). This product belongs to Category 4 chemical drugs and is deemed to have passed the consistency evaluation. Letermovir injection is mainly used for cytomegalovirus (CMV) seropositive adult recipients who have received allogeneic hematopoietic stem cell transplantation to prevent cytomegalovirus infection and cytomegalovirus disease. It needs to be used in combination with basic infusion and should be used in the perioperative period of hematopoietic stem cell transplantation. Relying on the existing advantages of basic infusion, the Group continues to improve the therapeutic injection product pipeline, and this approval further enriches the perioperative product portfolio.

#stem cells #Chemical #Gene #cell #Virus #generic drugs #chemicals #Hong Kong stock trends09-10 12:04

[National Bureau of Disease Control and Prevention releases popular science questions and answers on influenza vaccination] On September 7, the National Administration of Disease Control and Prevention released popular science questions and answers on influenza vaccination. Currently, seasonal epidemics are mainly caused by the H1N1 and H3N2 subtypes of influenza A virus and the Victoria strain of influenza B virus. The dominant strains vary in different epidemic seasons. Even within the same epidemic season, different types and subtypes of influenza viruses may alternately become dominant strains. Since the influenza virus mutates frequently, and the level of protective antibodies produced after vaccination gradually attenuates over time, the protective effect of the influenza vaccine generally lasts for 6 to 8 months, so the influenza vaccine needs to be vaccinated every year. Compared with the previous year, all three vaccine components have been updated this year. The components of the trivalent influenza vaccine produced in chicken embryos in the northern hemisphere recommended by the World Health Organization from 2026 to 2027 are: A/Missouri/11/2025 (H1N1)pdm09-like virus; A/Darwin/1454/2025 (H3N2)-like virus; B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus.

#Line #EA #Virus #vaccine #influenza09-07 22:10

[Hualan Biological: Its controlled subsidiary has been approved for clinical trials of the new influenza virus mRNA vaccine] On September 7, Hualan Biological (002007.SZ) announced that the company's controlled subsidiary Hualan Biological Vaccine received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration, agreeing to conduct clinical trials of the new influenza virus mRNA vaccine to prevent influenza. This vaccine is the first influenza virus mRNA vaccine in China to obtain implicit permission for clinical trials. Its research and development has entered the clinical trial stage, and there are still uncertainties in the follow-up.

#clinical trial #RNA #Virus #vaccine #A-share announcement express09-07 18:36

[Domestic first AI-assisted innovative drug approved for marketing] September 6th, according to news from Westlake University, the innovative drug - isestrevir hydrochloride tablets (trade name: Elpresvir) jointly developed by Westlake University, Westlake Laboratory, and Westlake Pharmaceuticals has recently been officially approved by the National Medical Products Administration with conditional approval for marketing. This is the first Class 1 innovative drug completely independently developed by Westlake University and is used for the treatment of mild and medium-sized novel coronavirus infections in adults. Category 1 innovative drugs are the highest level in China's drug registration classification, representing source innovation from 0 to 1. Its core lies in having a new chemical structure, a new mechanism of action, and having clear clinical value.

#Chemical #Virus #Overseas commodities #AI #Innovative drugs09-06 15:07

[The first domestically produced long-acting respiratory syncytial virus preventive monoclonal antibody is approved] On September 4, Simcere Pharmaceuticals announced that the domestic Class 1 bio-innovative drug Culevibizumab Injection (trade name: Inmulac), a strategic collaboration between it and Ruiyang (Shandong) Biopharmaceutical Co., Ltd., was approved for marketing by the National Medical Products Administration, becoming China’s first domestically produced long-acting preventive monoclonal antibody against respiratory syncytial virus (RSV) approved for marketing.

#biopharmaceutical #clone #Virus #medicine #Pharmaceutical business09-04 19:43

[Zhifei Bio: Supplementary Application for Influenza Virus Split Vaccine Accepted] On September 4th, Zhifei Bio (300122.SZ) announced that the supplementary application for the influenza virus split vaccine independently developed by Zhifei Longkoma, a wholly-owned subsidiary of the company, has been accepted by the State Food and Drug Administration, and it plans to add "children aged 6-35 months" to the approved population of 3 years old and above. The vaccine has been approved for marketing in September 2025. If it goes well, it will expand the applicable population and form a full age group coverage with the company's existing influenza vaccine products, strengthening market competitiveness. This supplementary application will have no significant impact on recent performance, and subsequent procedures such as technical review are subject to uncertainty.

#Virus #vaccine #A-share announcement express09-04 16:01

[The first domestically produced long-acting RSV preventive monoclonal antibody is approved] On September 4, Ruiyang Biopharmaceutical Co., Ltd.’s bakumab injection (trade name: Inmulex) was approved for marketing by the State Food and Drug Administration on September 3. It is the first domestically produced long-acting preventive monoclonal antibody against respiratory syncytial virus (RSV) approved for marketing. Simcere Pharmaceuticals has the exclusive rights to commercialize this product in Greater China.

#Virus #monoclonal antibody09-04 12:57

[Tylenumab: Riteviribumab injection has been approved for marketing by the State Food and Drug Administration] On September 3, Tylenumab (688806.SH) announced that the company received a notice from the State Food and Drug Administration to approve the independently developed Class 1 innovative drug Riteviribumab injection for children through the priority review and approval process. This product is suitable for preventing lower respiratory tract infections caused by RSV in newborns and infants who are about to enter or are born in the first respiratory syncytial virus epidemic season. Key Phase III clinical trials showed that within 150 days after administration, the protective efficacy against RSV lower respiratory tract infections requiring medical treatment and hospitalization resulted in 71.3% and 71.7%, and the protective efficacy against severe RSV LRT increased to 93.9% and 90.1%. This product is the world's first RSV monoclonal antibody with clinical protection data of up to nine months after one injection. This approval marks the successful launch of the company’s second independently developed fully human monoclonal antibody innovative drug.

#clinical trial #clone #Virus #A-share announcement express09-03 16:54

[National Administration for Disease Control and Prevention: The risk of epidemics of common infectious diseases in schools such as influenza has increased] On September 3, the National Administration for Disease Control and Prevention held a press conference today with the theme of "Scientific Disease Prevention to Start the School Season and Healthy Escort for the New Semester." Xi Jingjing, spokesperson of the National Administration of Disease Control and Prevention, briefed on the recent analysis of the epidemic situation of key infectious diseases and health risk warnings. With the heat of summer and autumn, the seasons change, and the epidemic situation of infectious diseases changes accordingly. The vector Aedes mosquito continues to be active in southern provinces, and mosquito-borne infectious diseases such as dengue fever and chikungunya are still in epidemic season. The national COVID-19 epidemic has been declining for three consecutive weeks, the influenza epidemic has fluctuated at a low epidemic level, and the epidemic of enteric infectious diseases has generally been at a low level. At the same time, we have now entered the golden autumn school season, and many students are returning to school. Affected by factors such as the concentration of personnel, environmental changes, and work and rest adjustments, the risk of common infectious diseases in schools such as influenza, norovirus infection, and hand, foot, and mouth disease has increased.

#Virus09-03 15:12

[Hidden immune cells in the lungs can prevent viruses from "taking root" in the respiratory tract] September 3rd, a new study conducted by a research team at the University of Rochester School of Medicine in the United States found that a previously ignored immune cell in the lungs can prevent viruses from "taking root" in the respiratory tract, thus helping to produce better flu vaccines. The relevant paper was published in the new issue of the journal Nature Immunology.

#Immunology #medicine #cell #Virus #vaccine #Global market intelligence09-03 07:04